Skip navigation

The following active life science portfolio companies and select exits are, or were, managed by members of the Lightstone team in the healthcare portfolios of Morgenthaler and/or ATV as indicated.

Alexo Therapeutics
>

Alexo Therapeutics

Alexo Therapeutics is a biopharmaceutical company developing novel biologics to help the immune system eradicate cancer.

Lightstone Lead: Jason Lettmann
Fund: Lightstone Ventures I
Location: Dublin, Ireland
Asterand Bioscience
>

Asterand Bioscience

Asterand Bioscience provides tissue and tissue-based research solutions for pharmaceutical, biotechnology, and diagnostic R&D.

Lightstone Lead: Chris Christoffersen, Ph.D.
Fund: Morgenthaler
Location: Cambridge, MA
Carrick Therapeutics
>

Carrick Therapeutics

Carrick Therapeutics is building an innovative portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer.

Lightstone Lead: Jason Lettmann
Fund: Lightstone Ventures I
Location: Dublin, Ireland
Cerevance
>

Cerevance

Cerevance is a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric disorders

Lightstone Lead: Jason Lettmann
Fund: Lightstone Ventures I
Location: Boston, MA
Elcelyx
>

Elcelyx

Elcelyx is a biopharmaceutical company developing a wide range of products based on the science of nutrient sensing. The therapies are directed at the treatment of diabetes and obesity.

Fund: Morgenthaler
Location: San Diego, CA
Hydra Biosciences
>

Hydra Biosciences

Hydra Biosciences is a biopharmaceutical company developing novel drugs to treat pain, inflammation, anxiety and other diseases using its expertise in novel ion channels.

Lightstone Lead: Jean George
Legacy Fund: ATV
Location: Cambridge, MA
Mosaic Biosciences
>

Mosaic Biosciences

Mosaic Biosciences is developing synthetic materials for native tissue regeneration. Applications include wound healing, bone regeneration, cartilage repair, stem cell therapy, and dermal fillers.

Lightstone Lead:
Legacy Fund: Morgenthaler
Location: Boulder, CO
Nimbus Therapeutics
>

Nimbus Therapeutics

Nimbus Therapeutics is a biotechnology company that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was formed using an LLC model. Its lead program was acquired by Gilead Sciences in 2016.

 

Lead program acquired by Gilead Sciences (NASDAQ: GILD)

Lightstone Lead: Chris Christoffersen, Ph.D.
Fund: Lightstone Ventures I
Location: Cambridge, MA
Principia
>

Principia

Principia is a biopharmaceutical company developing novel compounds with enhanced sensitivity, high potency, and longer duration of effect.

Lightstone Lead:
Legacy Fund: Morgenthaler
Location: Menlo Park, CA
Promedior
>

Promedior

Promedior Pharmaceuticals is a biopharmaceutical company developing a proprietary platform of pentraxin therapeutics for the treatment of fibrosis.

Lightstone Lead: Jason Lettmann
Fund: Morgenthaler
Location: Lexington, MA
Second Genome
>

Second Genome

Second Genome is a biopharmaceutical company targeting the human microbiome to discover novel therapies for infection, inflammation, and metabolic diseases.

Lightstone Lead:
Fund: ATV & Morgenthaler
Location: San Bruno, CA
Thrasos Therapeutics
>

Thrasos Therapeutics

Thrasos is a biotherapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of kidney disease.

Lightstone Lead: Jean George
Legacy Fund: ATV
Location: Montreal, QC
Tizona Therapeutics
>

Tizona Therapeutics

Tizona Therapeutics is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases.

Lightstone Lead: Jean George
Fund: Lightstone Ventures I
Location: South San Francisco, CA
Tragara
>

Tragara

Tragara Pharmaceuticals is a biopharmaceutical company developing proprietary drugs for the treatment of various cancers.

Lightstone Lead: Chris Christoffersen, Ph.D.
Legacy Fund: Morgenthaler
Location: San Diego, CA
Acceleron
>

Acceleron

Acceleron Pharma is a biopharmaceutical company focused on the development and commercialization of novel protein therapeutics for orphan diseases and cancer based on the TGF-β protein superfamily. The company had an IPO in 2013.

 

NASDAQ: XLRN

Lightstone Lead: Jean George
Fund: ATV
Location: Cambridge, MA
Avidia
>

Avidia

Avidia is a biopharmaceutical company focused on discovering and developing a new class of human therapeutic proteins called avimers™. The company was acquired by Amgen in 2006.

Aquired by Amgen (NASDAQ: AMGN)

Lightstone Lead: Chris Christoffersen, Ph.D.
Legacy Fund: Morgenthaler
Location: Mountain View, CA
Calithera
>

Calithera

Calithera Biosciences is a biopharmaceutical company developing novel therapeutics for the treatment of cancer and other proliferative diseases by targeting the dysregulated metabolic pathways of cancer cells. The company had an IPO in 2014.

 

NASDAQ: CALA

Fund: ATV & Morgenthaler
Location: South San Francisco, CA
Catabasis
>

Catabasis

Catabasis is leveraging the therapeutic potential of omega-3 fatty acids and other clinically validated compounds to create new medicines for the treatment of inflammatory and metabolic diseases. The company had an IPO in 2015.

 

NASDAQ: CATB

Lightstone Lead: Jean George
Fund: LSV & ATV
Location: Cambridge, MA
Catalyst Biosciences
>

Catalyst Biosciences

Catalyst Biosciences is developing therapeutics that utilize protease enzymes as biopharmaceuticals. Catalyst calls these redirected engineered proteases "Alterase™ Therapeutics." The company completed a reverse merger with Targacept in 2015.

 

NASDAQ: CBIO

Lightstone Lead: Chris Christoffersen, Ph.D.
Fund: Morgenthaler
Location: South San Francisco, CA
FivePrime
>

FivePrime

FivePrime Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of a complete range of innovative protein and antibody drugs. The company had an IPO in 2013.

 

NASDAQ: FPRX

Lightstone Lead: Jean George
Fund: ATV
Location: South San Francisco, CA
Flex Pharma
>

Flex Pharma

Flex Pharma is a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders, and has demonstrated initial human efficacy related to muscle cramping. The company had an IPO in 2015.

 

NASDAQ: FLKS

Lightstone Lead: Jean George
Fund: Lightstone Ventures I
Location: Boston, MA
FoldRx
>

FoldRx

FoldRx Pharmaceuticals, Inc. is a biopharmaceutical company developing disease modifying drug therapies for diseases of protein misfolding and amyloidosis.

Acquired by Pfizer (NYSE: PFE)

Lightstone Lead: Chris Christoffersen, Ph.D.
Legacy Fund: Morgenthaler
Location: Cambridge, MA
Hypnion
>

Hypnion

Hypnion is a biopharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders such as sleep, wake-alertness disorders, circadian rhythm abnormalities.

Acquired by Eli Lilly (NYSE: LLY)

Lightstone Lead: Jean George
Legacy Fund: ATV
Location: Lexington, MA
Morphotek
>

Morphotek

Morphotek is a biopharmaceutical company developing novel classes of biological-based products to treat cancer, inflammation and infectious diseases. The company was acquired by Eisai Inc. in 2007.

 

Acquired by Eisai (TYO: 4523)

 

Lightstone Lead: Chris Christoffersen, Ph.D.
Fund: Morgenthaler
Location: Exton, PA
Nimbus Therapeutics
>

Nimbus Therapeutics

Nimbus Therapeutics is a biotechnology company that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was formed using an LLC model. Its lead program was acquired by Gilead Sciences in 2016.

 

Lead program acquired by Gilead Sciences (NASDAQ: GILD)

Lightstone Lead: Chris Christoffersen, Ph.D.
Fund: Lightstone Ventures I
Location: Cambridge, MA
OncoMed
>

OncoMed

OncoMed is developing monoclonal antibodies that target tumor initiating cells, also known as "cancer stem cells." The company had an IPO in 2013.

 

NASDAQ:OMED

Lightstone Lead:
Fund: Morgenthaler
Location: Redwood City, CA
Orexigen
>

Orexigen

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for the treatment of obesity. The company had an IPO in 2007.

NASDAQ: OREX

Lightstone Lead: Chris Christoffersen, Ph.D.
Legacy Fund: Morgenthaler
Location: La Jolla, CA
Plexxikon
>

Plexxikon

Plexxikon is developing novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to develop a portfolio of competitively differentiated therapeutic programs. The company was acquired by Daiichi Sankyo in 2011.

Acquired by Daiichi Sankyo (TYO: 4568)

Lightstone Lead: Mike Carusi
Fund: ATV
Location: Berkeley, CA
Portola
>

Portola

Portola is developing innovative therapeutics for cardiovascular and autoimmune/inflammatory diseases. The company had an IPO in 2013.

 

NASDAQ: PTLA

 

Lightstone Lead: Jean George
Fund: ATV
Location: South San Francisco, CA
Proteolix
>

Proteolix

Proteolix is a biopharmaceutical company developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.

Acquired by Onyx (NASDAQ: ONXX)

Lightstone Lead: Jean George
Legacy Fund: ATV
Location: South San Francisco, CA
Ra Pharma
>

Ra Pharma

Ra Pharmaceuticals is developing a new class of drugs with the specificity of antibodies and the oral bioavailability of small molecules.  The company had an IPO in 2016.

 

NASDAQ:RARX

Lightstone Lead: Jason Lettmann
Fund: Morgenthaler & Lightstone Ventures I
Location: Cambridge, MA
Scioderm
>

Scioderm

Scioderm is focused on the development of innovative drugs for the treatment of chronic diseases of the skin. The company was acquired by Amicus Therapeutics in 2015.

 

Acquired by Amicus Therapeutics (NASDAQ: FOLD)

Lightstone Lead: Chris Christoffersen, Ph.D.
Fund: Morgenthaler
Location: Durham, NC.
Threshold
>

Threshold

Threshold Pharmaceuticals is developing therapeutics based on tumor hypoxia, a platform that offers potential to treat most solid tumors. The company had an IPO in 2005.

NASDAQ: THLD

Lightstone Lead: Chris Christoffersen, Ph.D.
Legacy Fund: Morgenthaler
Location: South San Francisco, CA
Verastem
>

Verastem

Verastem is bringing breakthroughs in cancer stem cell research into new medicines for the treatment of major cancers, such as breast cancer. The company had an IPO in 2012.

NASDAQ: VSTM

Lightstone Lead: Jean George
Legacy Fund: ATV
Location: Cambridge, MA
';